Opaleye Management Buys 300 Shares of SOL‑GEL at $73.69, Bolstering Confidence Amid 804% YTD Rally

Opaleye Management’s Recent Buy in SOL‑GEL Technologies

Opaleye Management Inc. added 300 shares of SOL‑GEL Technologies on July 8, 2026, paying an average price of $73.69 per share—just below the day’s close of $76.36. The transaction comes at a time when the stock is trading near its 52‑week low of $7.62, yet still riding a remarkable 804 % year‑to‑date rally. With a market cap of roughly $256 million, the firm remains a small‑cap, high‑growth player in the pharmaceutical space, and the buy is noteworthy for its timing and volume relative to the company’s total shares outstanding.

What the Deal Signals for Investors

The purchase follows a string of incremental acquisitions by Opaleye throughout the year—most recently a sizeable 1,400‑share purchase at $71.97 on July 2 and a 1,563‑share buy at $64.43 in May. These consistent “top‑up” transactions suggest a confidence‑driven strategy rather than a speculative spike. For investors, this could be a bullish cue that the asset‑manager sees value in SOL‑GEL’s pipeline of topical dermatology products, especially as the company’s clinical studies enter later stages. The modest price decline of 0.03 % on the transaction date, coupled with a 222 % buzz in social‑media chatter, indicates that the market is still digesting the news rather than reacting negatively.

Opaleye Management Inc.: A Profile of Activity

Opaleye Management has maintained a steady, long‑term stake in SOL‑GEL, accumulating over 500,000 shares since the IPO in 2018. Their purchases have typically hovered in the $40–$80 range, reflecting a disciplined, dollar‑cost‑averaging approach. Historically, Opaleye’s trades have been mostly “buy” transactions with no significant sales or wash trades reported. This pattern positions Opaleye as a supportive, patient investor rather than an opportunistic trader. Their holdings also include a 15,000‑share “managed account” block, indicating that they are not only investing their own capital but also managing external funds in SOL‑GEL.

Implications for SOL‑GEL’s Future

The incremental capital infusion from Opaleye, combined with the company’s strong annual growth trajectory and expanding clinical pipeline, could translate into additional R&D funding or a strategic partnership. The fact that the company is trading near its lowest level of the year presents a potential “buy the dip” opportunity for the broader market, especially if the clinical data continue to be positive. However, investors should keep an eye on the company’s negative price‑earnings ratio and the volatility of its share price, which may still pose downside risk.

Bottom Line for Market Participants

Opaleye Management’s latest purchase is a measured, confidence‑driven move that reinforces the company’s long‑term interest in SOL‑GEL Technologies. For shareholders, it may signal a sustainable support level amid a highly volatile, high‑growth environment. Market participants should view this transaction as a positive sign of institutional backing, but remain cognizant of the broader risks inherent in a clinical‑stage pharmaceutical venture.